Back to Browse Journals » Drug Design, Development and Therapy » Volume 4

Drug Design, Development and Therapy


Archive: Volume 4, 2010

Comparative bioequivalence studies of tramadol hydrochloride sustained-release 200 mg tablets

Suhas S Khandave, Satish V Sawant, Santosh S Joshi, et al

Drug Design, Development and Therapy 2010, 4:367-374

Published Date: 25 November 2010

New approaches in the management of multiple sclerosis

Laurie J Barten, Douglas R Allington, Kendra A Procacci, et al

Drug Design, Development and Therapy 2010, 4:343-366

Published Date: 24 November 2010

Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine

Linda Steinbaugh, Jerzy P Szaflarski

Drug Design, Development and Therapy 2010, 4:337-342

Published Date: 18 November 2010

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections

Emily Zoller, Connie Valente, Kyle Baker, et al

Drug Design, Development and Therapy 2010, 4:299-311

Published Date: 4 November 2010

Silodosin in the treatment of benign prostatic hyperplasia

Maxime Rossi, Thierry Roumeguère

Drug Design, Development and Therapy 2010, 4:291-297

Published Date: 27 October 2010

Liraglutide in the management of type 2 diabetes

Estela Wajcberg, Amatur Amarah

Drug Design, Development and Therapy 2010, 4:279-290

Published Date: 22 October 2010

Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy

Aarat M Patel, Larry W Moreland

Drug Design, Development and Therapy 2010, 4:263-278

Published Date: 1 October 2010

Thermosensitive Pluronic® hydrogel: prolonged injectable formulation for drug abuse

Katayoun Derakhshandeh, Mahtab Fashi, Seyedalireza Seifoleslami

Drug Design, Development and Therapy 2010, 4:255-262

Published Date: 20 September 2010

Current and developing therapeutic agents in the treatment of Chagas disease

Werner Apt

Drug Design, Development and Therapy 2010, 4:243-253

Published Date: 17 September 2010

Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B

Thomas Scior, José Antonio Guevara-García, FJ Melendez, et al

Drug Design, Development and Therapy 2010, 4:231-242

Published Date: 23 September 2010

Safety and efficacy of azacitidine in myelodysplastic syndromes

Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero

Drug Design, Development and Therapy 2010, 4:221-229

Published Date: 9 September 2010

Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome

Son V Pham, Phuong-Chi T Pham, Phuong-Mai T Pham, et al.

Drug Design, Development and Therapy 2010, 4:203-220

Published Date: 6 September 2010

Emerging treatments in the management of schizophrenia – focus on sertindole

Maria Rosaria A Muscatello, Antonio Bruno, Gianluca Pandolfo, et al

Drug Design, Development and Therapy 2010, 4:187-201

Published Date: 24 August 2010

Development of QSAR model for immunomodulatory activity of natural coumarinolignoids

Dharmendra K Yadav, Abha Meena, Ankit Srivastava, et al

Drug Design, Development and Therapy 2010, 4:173-186

Published Date: 30 July 2010

A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy

Samuel L Washington III, Alan W Shindel

Drug Design, Development and Therapy 2010, 4:159-171

Published Date: 4 August 2010

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD

Mark A Giembycz, Stephen K Field

Drug Design, Development and Therapy 2010, 4:147-158

Published Date: 14 July 2010

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine

Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, et al

Drug Design, Development and Therapy 2010, 4:117-126

Published Date: 18 June 2010

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders

Pär I Johansson, Sisse R Ostrowski

Drug Design, Development and Therapy 2010, 4:107-116

Published Date: 29 June 2010

Development of a sublingual allergy vaccine for grass pollinosis

Franco Frati, Silvia Scurati, Paola Puccinelli, et al

Drug Design, Development and Therapy 2010, 4:99-105

Published Date: 17 June 2010

Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)

M Tiseo, M Bartolotti, F Gelsomino, et al

Drug Design, Development and Therapy 2010, 4:81-98

Published Date: 19 May 2010

ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile

Aysegul Nalca, Elizabeth E Zumbrun

Drug Design, Development and Therapy 2010, 4:71-79

Published Date: 17 May 2010

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension

Gautam V Ramani, Myung H Park

Drug Design, Development and Therapy 2010, 4:61-70

Published Date: 6 May 2010

New anticoagulants for the prevention of venous thromboembolism

Cecilia Becattini, Alessandra Lignani, Giancarlo Agnelli

Drug Design, Development and Therapy 2010, 4:49-60

Published Date: 7 April 2010

New atypical antipsychotics for schizophrenia: iloperidone

Silvio Caccia, Luca Pasina, Alessandro Nobili

Drug Design, Development and Therapy 2010, 4:33-48

Published Date: 15 February 2010

Continuation treatment of major depressive disorder: is there a case for duloxetine?

Trevor R Norman, James S Olver

Drug Design, Development and Therapy 2010, 4:19-31

Published Date: 12 February 2010

Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal

Chaouki K Khoury, James R Couch

Drug Design, Development and Therapy 2010, 4:9-17

Published Date: 25 January 2010

Corrigendum

Nusrat Motlekar, Bi-Botti Youan

Drug Design, Development and Therapy 2010, 4:7-8

Published Date: 26 January 2010

Recent advances in the treatment of premature ejaculation

Kate D Linton, Kevan R Wylie

Drug Design, Development and Therapy 2010, 4:1-6

Published Date: 5 January 2010